Literature DB >> 6286120

Phase II trial of m-AMSA in hepatocellular carcinoma: a Southwest Oncology Group Study.

R M Bukowski, S Legha, J Saiki, H J Eyre, R O'Bryan.   

Abstract

Twenty-three patients with heptocellular carcinoma were treated with m-AMSA at a dose of 120 mg/m2 iv repeated at 4-week intervals. Toxicity was primarily hematologic. Partial responses occurred in two of 14 previously treated patients and in one of nine previously untreated patients. The overall activity of m-AMSA in patients with hepatocellular carcinoma appears minimal.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6286120

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  4 in total

1.  The effect of cimetidine, phenobarbitone and buthionine sulphoximine on the disposition of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in the rabbit.

Authors:  J W Paxton; P C Evans; J R Hardy
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Dose-dependent pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in rabbits.

Authors:  J W Paxton; P C Evans; R M Singh
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4 -acridinecarboxamide (CI-921) in a phase 1 trial.

Authors:  J W Paxton; J R Hardy; P C Evans; V J Harvey; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

4.  Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino] -4-acridinecarboxamide in rabbits.

Authors:  J W Paxton; J L Jurlina
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.